Award Winner
Dr Zhang Jingjing
Principal Investigator, Nanomedicine Translational Research Programme,
NUS Yong Loo Lin School of Medicine
Principal Investigator, Nanomedicine Translational Research Programme,
NUS Yong Loo Lin School of Medicine
On April 9th, our recently work about the DNA origami device which can spatially control CD95 signalling to induce immune
Theranostics has just received its latest Impact Factor for the year 2022, which is 12.4. It ranks 8th among 136
Abstract The metabolic reprogramming of tumors requires high levels of adenosine triphosphate (ATP) to maintain therapeutic resistance, posing a major